Loading stock data…
Penumbra (PEN)
$315.46-1.17 (-0.37%)
After Hours$315.46+0.00 (+0.00%)· Last close Jun 29
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Penumbra, Inc. in the Healthcare sector is trading at $315.46 with a market capitalization of $12.5B. Wall Street consensus targets $364.43 (14 analysts), implying a +15.5% move over the next 12 months. The stock is currently 13% below its 52-week high of $362.41, remaining 2.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $374.76M↓ | $385.38M↑ | $354.69M↑ | $339.45M↑ | $324.14M |
| Gross Profit | $253.41M↓ | $262.13M↑ | $240.42M↑ | $224.01M↑ | $215.88M |
| Operating Income | $38.23M↓ | $59.23M↑ | $48.84M↑ | $40.83M↑ | $40.35M |
| Net Income | $32.58M↓ | $47.34M↑ | $45.85M↑ | $45.27M↑ | $39.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the In...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
11.61%
Volume
Today's trading volume
271,090
Recent News
GMED vs. PEN: Which Stock Should Value Investors Buy Now?
GMED vs. PEN: Which Stock Is the Better Value Option?
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
PEN gains CE Mark in Europe for THUNDERBOLT, expanding stroke treatment access and advancing its global stroke care strategy.
ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Penumbra wins CE mark for Thunderbolt clot removal tech
The international launch could benefit from Boston Scientific’s global footprint when the company closes its takeover of Penumbra.
Medtech M&A maintains momentum following decade-high 2025: PwC
Deal volumes and values are tracking above the first half of 2025, driven by Boston Scientific’s Penumbra buyout and Danaher’s Masimo acquisition.